Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses

INTRODUCTION/AIMS: ALS is a heterogeneous disease that may be complicated or in part driven by inflammation. NP001, a regulator of macrophage activation, was associated with slowing disease progression in those with higher levels of the plasma inflammatory marker C‐reactive protein (CRP) in phase 2A...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Robert G., Zhang, Rongzhen, Bracci, Paige M., Azhir, Ari, Barohn, Richard, Bedlack, Richard, Benatar, Michael, Berry, James D., Cudkowicz, Merit, Kasarskis, Edward J., Mitsumoto, Hiroshi, Manousakis, Georgios, Walk, David, Oskarsson, Bjorn, Shefner, Jeremy, McGrath, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327716/
https://www.ncbi.nlm.nih.gov/pubmed/35098554
http://dx.doi.org/10.1002/mus.27511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327716/
https://www.ncbi.nlm.nih.gov/pubmed/35098554
http://dx.doi.org/10.1002/mus.27511

Ejemplares similares